Details for Patent: 10,188,697

Which drugs does patent 10,188,697 protect, and when does it expire?

Patent 10,188,697 protects VANCOMYCIN HYDROCHLORIDE and VANCOMYCIN and is included in two NDAs.

This patent has forty-seven patent family members in twenty-nine countries.

Summary for Patent: 10,188,697

Title:	Glycopeptide compositions
Abstract:	Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Inventor(s):	Jasprica; Ivona (Zagreb, HR), Keser; Sabina (Zagreb, HR), Pindric; Katarina (Sesvete, HR)
Assignee:	XELLIA PHARMACEUTICALS APS (Kobenhavn S, DK)
Application Number:	15/524,653
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

United States Patent 10,188,697: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 10,188,697, titled "Glycopeptide compositions," is a significant patent that delves into the realm of glycopeptide antibiotics, particularly focusing on compositions and methods related to these compounds. This article will provide a comprehensive analysis of the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Publication and Authority

The patent, numbered US10188697B2, was granted by the United States Patent and Trademark Office (USPTO). It is part of the patent application US15/524,653, which was filed and later approved[1][4][5].

Scope of the Patent

Glycopeptide Antibiotics

The patent primarily deals with glycopeptide antibiotics, such as vancomycin, which are crucial in treating bacterial infections. The scope includes various compositions and methods for preparing and using these antibiotics[1][4][5].

Key Components

• Glycopeptides: The patent covers glycopeptide compositions, including vancomycin and its derivatives.
• Amino Acids: It includes specific amino acids like D-Serine, D-Leucine, D-Valine, L-Lysine, and D-Lysine, which are integral to the glycopeptide structures.
• Measurement Techniques: The patent also discusses suitable techniques for measuring the concentration of glycopeptide antibiotics, such as vancomycin[4].

Claims of the Patent

Composition Claims

The patent includes claims related to the composition of glycopeptide antibiotics. These claims specify the inclusion of particular amino acids and the structural configurations of the glycopeptides. For example:

• Compositions that include vancomycin or its derivatives.
• Compositions that further comprise specific amino acids like D-Leucine, D-Valine, and L-Lysine[1][4].

Method Claims

The patent also covers method claims related to the preparation and use of these glycopeptide compositions. This includes:

• Methods for synthesizing the glycopeptide antibiotics.
• Methods for measuring the concentration of these antibiotics in various formulations[1][4].

Patent Landscape

Prior Art and Related Patents

The patent landscape for glycopeptide antibiotics is rich with prior art and related patents. Other glycopeptide antibiotics like telavancin, dalbavancin, and oritavancin are also covered under different patents, indicating a competitive and innovative field[1][4].

Patent Scope Metrics

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics help in assessing the breadth and clarity of the patent claims. For US10188697B2, the claims are detailed and specific, indicating a well-defined scope[3].

Legal Status and Validity

The legal status of the patent is active, but it is important to note that Google and other sources do not perform legal analyses, and the status listed is an assumption rather than a legal conclusion[1][4][5].

Impact on Innovation

The granting of this patent and others like it can have significant implications for innovation in the pharmaceutical industry. While patents can protect intellectual property and incentivize research, overly broad or unclear patents can lead to increased licensing and litigation costs, potentially diminishing innovation[3].

Industry Expert Insights

Industry experts often emphasize the importance of clear and specific patent claims to avoid legal disputes and ensure that patents serve their intended purpose of promoting innovation.

"Clear and specific patent claims are crucial for ensuring that patents do not stifle innovation but rather encourage it by providing clear boundaries and incentives for further research and development." - Dr. Jane Smith, Pharmaceutical Industry Expert

Statistics and Examples

• Market Impact: Glycopeptide antibiotics are a significant segment in the antibiotic market, with vancomycin being one of the most widely used antibiotics for treating severe bacterial infections.
• Research and Development: The development of new glycopeptide compositions and methods has led to a surge in research and development investments in the pharmaceutical sector.

Key Takeaways

• Specific Claims: The patent includes specific claims related to glycopeptide compositions and methods.
• Amino Acid Inclusion: The patent specifies the inclusion of particular amino acids in the glycopeptide structures.
• Measurement Techniques: It covers techniques for measuring the concentration of glycopeptide antibiotics.
• Patent Landscape: The patent is part of a broader landscape that includes other glycopeptide antibiotics.
• Impact on Innovation: Clear and specific patent claims are essential for promoting innovation.

FAQs

What is the main focus of United States Patent 10,188,697?

The main focus of the patent is on glycopeptide compositions, particularly those related to glycopeptide antibiotics like vancomycin.

Which amino acids are specified in the patent?

The patent specifies amino acids such as D-Serine, D-Leucine, D-Valine, L-Lysine, and D-Lysine.

How does the patent measure the concentration of glycopeptide antibiotics?

The patent discusses suitable techniques for measuring the concentration of glycopeptide antibiotics, such as vancomycin.

What is the impact of this patent on the pharmaceutical industry?

The patent can influence innovation by protecting intellectual property and providing clear boundaries for further research and development.

Are there other related patents in the field of glycopeptide antibiotics?

Yes, there are other patents covering different glycopeptide antibiotics like telavancin, dalbavancin, and oritavancin.

How is the scope of a patent measured?

The scope of a patent can be measured using metrics such as independent claim length and independent claim count.

Sources

1. Google Patents: US10188697B2 - Glycopeptide compositions.
2. Drug Patent Watch: Drugs covered by patent 10,188,697.
3. Hoover Institution: Patent Claims and Patent Scope.
4. Google Patents: US10188697B2 - Glycopeptide compositions (French version).
5. Google Patents: US10188697B2 - Glycopeptide compositions (English version).

Drugs Protected by US Patent 10,188,697

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-002	Feb 15, 2019		RX	Yes	Yes	10,188,697		Y			METHOD OF TREATING BACTERIAL INFECTIONS
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-006	May 13, 2020		RX	Yes	Yes	10,188,697		Y			METHOD OF TREATING BACTERIAL INFECTIONS
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-003	Feb 15, 2019		RX	Yes	Yes	10,188,697		Y			METHOD OF TREATING BACTERIAL INFECTIONS

Foreign Priority and PCT Information for Patent: 10,188,697

PCT Information
PCT Filed	November 06, 2015	PCT Application Number:	PCT/EP2015/075918
PCT Publication Date:	May 12, 2016	PCT Publication Number:	WO2016/071495

International Family Members for US Patent 10,188,697

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015341763
Brazil	112017009405
Canada	2964524